Searched for: +
(1 - 3 of 3)
Zadelaar, A.S.M. (author), Boesten, L.S.M. (author), Jukema, J.W. (author), van Vlijmen, B.J.M. (author), Kooistra, T. (author), Emeis, J.J. (author), Lundholm, E. (author), Camejo, G. (author), Havekes, L.M. (author), Gaubius Instituut TNO (author)
OBJECTIVE - We investigated whether the dual PPARα/γ agonist tesaglitazar has anti-atherogenic effects in ApoE*3Leiden mice with reduced insulin sensitivity. METHODS AND RESULTS - ApoE*3Leiden transgenic mice were fed a high-fat (HF) insulin-resistance-inducing diet. One group received a high-cholesterol (HC) supplement (1% wt/wt; HC group). A...
article 2006
Trion, A. (author), de Maat, M.P.M. (author), Jukema, J.W. (author), van der Laarse, A. (author), Maas, M.C. (author), Offerman, E.H. (author), Havekes, L.M. (author), Szalai, A.J. (author), Princen, H.M.G. (author), Emeis, J.J. (author), TNO Kwaliteit van Leven (author)
Objective - C-reactive protein (CRP) has been associated with risk of cardiovascular disease. It is not clear whether CRP is causally involved in the development of atherosclerosis. Mouse CRP is not expressed at high levels under normal conditions and increases in concentration only several-fold during an acute phase response. Because the...
article 2005
van Nieuw Amerongen, G.P. (author), Vermeer, M.A. (author), Negre-Aminou, P. (author), Lankelma, J. (author), Emeis, J.J. (author), van Hinsbergh, V.W.M. (author), Gaubius Instituut TNO (author)
Background - Recent clinical trials have established that inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) reduce the risk of acute coronary events. These effects of statins cannot be fully explained by their lipid-lowering potential. Improved endothelial function may contribute to the positive effects of statin...
article 2000